Form 4: Boundless Bio Executive Christian Hassig Reports Stock Option Repricing

Christian Hassig, Chief Scientific Officer of Boundless Bio, reports the repricing of stock options on August 19, 2024, according to a Form 4 filing with the SEC.

Summary

• Christian Hassig, Chief Scientific Officer of Boundless Bio, filed a Form 4 with the SEC on August 20, 2024.
• The filing reports the repricing of several stock option grants on August 19, 2024.
• The repricing adjusted the exercise price of the options to $3.56 per share, representing the fair market value on the repricing date.
• The original exercise prices for the options ranged from $3.71 to $16.
• The repriced options cover a total of 292,783 shares of common stock.
• The vesting schedules for the options remain largely unchanged, with monthly installments beginning at various dates in 2021, 2023 and 2024.
• A clause was added that the exercise price will revert to the original price if the option is exercised or employment is terminated before August 19, 2026, or a change in control, unless the termination is a 'qualifying termination'.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The repricing could be seen as slightly positive as it incentivizes the executive, but it also suggests the stock price may have underperformed.

Positives

• The repricing of stock options could incentivize the executive by aligning the option exercise price with the current fair market value.

Risks

• The clause that reverts the exercise price to the original price under certain conditions could be viewed as a disincentive if those conditions are triggered.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's financial performance or future prospects.

Industry Context

Stock option repricing is a common practice used by companies to incentivize employees, especially when the stock price has declined. It ensures that options remain valuable and motivates employees to work towards increasing shareholder value.

Comparison to Industry Standards

• Stock option repricing is a fairly common practice in the biotech industry, especially for companies that have experienced a decline in their stock price.
• Many companies use similar vesting schedules, typically over a 4-year period with monthly installments.
• The specific terms of the repricing, such as the clause that reverts the exercise price under certain conditions, are company-specific and depend on their compensation policies.

Stakeholder Impact

• The repricing of stock options could potentially impact shareholder value if it incentivizes the executive to improve company performance.
• The repricing directly benefits the executive by making their stock options more valuable.

Key Dates